Board of Directors
Board of Directors
Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Since June 2018, Mr. Bradbury has served as Chief Executive Officer of Equillium, Inc., a publicly traded biotechnology company, where he also served as its President from March 2017 until June 2018. Mr. Bradbury is the founder of, and has served as the managing member of, BioBrit, LLC, a life sciences consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc. from March 2007 until Amylin’s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for ten years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury serves on the board of directors of numerous private companies and two publicly traded companies, Equillium, Inc. and Intercept Pharmaceuticals, Inc. He previously served on the board of directors of the following publicly traded companies: Corcept Therapeutics, Inc., from 2012 to 2019; Geron Corporation, from 2012 to 2019; and Illumina, Inc. from 2004 to 2017. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Founder, President, CEO, and Director
Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President and Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis). Mr. Maetzold currently serves as a director of the Ocular Melanoma Foundation. He has contributed to the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, has co-authored multiple scientific publications and is a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold holds a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside
Mara G. Aspinall has served as a member of our board of directors since February 2015. Ms. Aspinall has served as Managing Director of BlueStone Venture Partners, a life science-focused venture capital firm, since December 2017. Since June 2014, Ms. Aspinall has served as the President and Chief Executive Officer of Health Catalysts Group, a consulting firm that focuses on growth of early stage life science and technology companies. From September 2011 until June 2014, Ms. Aspinall served as the President and Chief Executive Officer of the Ventana Medical Systems and the Global Head of Roche Tissue Diagnostics, a global leader in the development and commercialization of tissue-based cancer diagnostics. Prior to 2011, Ms. Aspinall served as President of Genzyme Pharmaceuticals and Genzyme Genetics. Ms. Aspinall currently serves as a director of Allscripts Healthcare Solutions, Orasure Technologies and UK-based company Abcam plc., along with other privately-held healthcare technology and medical insurance companies. Ms. Aspinall holds a B.A. degree in International Relations from Tufts University and an MBA from Harvard Business School.
Kimberlee Caple has served as a member of our board of directors since July 2021. Since mid-2020, Ms. Caple has served as Vice President and General Manager, Genetic Science Business, at Thermo Fisher Scientific. The Genetic Science Business is made up of three business units which develop, manufacture and commercialize genetic analysis technologies that serve the healthcare, forensic, research and pharmaceutical/biotechnology markets globally. From 2017 through mid-2020, Ms. Caple was Vice President and General Manager for the capillary electrophoresis business unit, a part of the Genetic Science Business within Thermo Fisher Scientific. From 2015 through 2016, she was Vice President of Clinical Business at Affymetrix, responsible for microarray products serving the reproductive health and oncology clinical laboratory markets. Affymetrix was acquired by Thermo Fisher Scientific in 2016. Ms. Caple supported the integration of the Affymetrix business into a new microarray business unit within the Genetic Science Business of Thermo Fisher Scientific. Ms. Caple holds a B.S. degree in Biology from Purdue University.
G. Bradley Cole
G. Bradley Cole has served as a member of our board of directors since December 2018. From November 2019 until April 2020, Mr. Cole served as General Manager, Precision Oncology, a unit of Exact Sciences Corporation, a molecular diagnostics company, following Exact Science Corporation’s acquisition of Genomic Health, Inc. From June 2004 to November 2019, Mr. Cole served as Chief Financial Officer of Genomic Health, Inc., a publicly traded global provider of genomic-based diagnostic tests, where he also served as Chief Operating Officer from January 2009 until March 2018. Mr. Cole previously held Chief Financial Officer positions at multiple publicly traded companies, including Applied Biosciences, Inc. Since July of 2020, Mr. Cole has served on another public company board, Kiniksa Pharmaceuticals, and is a member of the audit committee. Mr. Cole holds a B.S. degree in Accounting from Biola University and an MBA from San Jose State University.
Ellen Goldberg has served as a member of our board of directors since July 2021. Ms. Goldberg is the Founder and President of CHORD Consulting, where she works with executives of innovative diagnostics companies to develop and commercialize novel products. She has focused her career on ground-breaking technologies in life-threatening and life-altering diseases. Previously, Ms. Goldberg was Vice President of Marketing at Crescendo Bioscience, where she launched Vectra DA®, a multi-biomarker blood test that enables treatment changes to improve outcomes in rheumatoid arthritis. Prior to Crescendo, Ms. Goldberg led marketing at Genomic Health, where she launched the Oncotype DX® Breast Cancer Assay, a standard of care test that empowers over 80,000 women annually to make more informed decisions about their treatment, and helped develop tests in colon cancer, prostate cancer and ductal carcinoma in situ (DCIS). Ms. Goldberg began her career as a strategy consultant with Booz Allen & Hamilton and developed new products at ALZA Corporation. She has an M.S in Chemistry and an MBA from Stanford University and a B.S. in Chemistry from Yale University. Ms. Goldberg is also a fellow of the Aspen Institute’s Health Innovators Fellowship Program.
Miles Harrison has served as a member of our board of directors since 2020. From 2016 through 2021, Mr. Harrison served as the North American President and General Manager of Galderma Laboratories, L.P., the largest independent global dermatology company. During his tenure, Galderma launched multiple brands and new indications across the company’s Prescription, Consumer and Aesthetic businesses. Mr. Harrison also served as Galderma’s Vice President and General Manager of the Consumer Business Unit from August 2014 until February 2016, where the first prescription to OTC switch in acne in more than 30 years was secured and successfully launched. Prior to Galderma, Mr. Harrison spent most of his career at Novartis. From June 1987 to February 2014, Mr. Harrison held multiple leadership positions of increasing responsibility, across the Consumer, Oncology and Pharmaceuticals businesses, most recently as Vice President and Head of Global Advocacy. Mr. Harrison holds a B.A. [Honors] Degree in Geography from Sheffield Hallam University in the United Kingdom and has worked in the UK, Europe, Middle East and Latin America, in addition to his U.S. based roles.
Tiffany Olson has served as a member of our board of directors since May 2021. Since 2013, Ms. Olson has served as president of Nuclear & Precision Health Solutions at Cardinal Health, which develops, manufactures, compounds, dispenses and delivers 12 million time-critical, patient specific doses annually to thousands of customers via a network of nuclear pharmacies and manufacturing sites that span the U.S. Prior to Cardinal Health, Ms. Olson was president of NaviMed, a company focused on personalizing medicine through innovative diagnostics. She also worked for Eli Lilly and Company, where she was tasked with leading the effort to formulate the strategy to create and commercialize diagnostics and companion diagnostics. Ms. Olson also worked for Roche Diagnostics, where she attained the position of president and chief executive officer of Roche Diagnostics Corporation. She was the first woman to receive the Life Science Alley Luminary Award, recognizing her “rich career in medical diagnostics…exceptional reputation as a leader and her vision to drive both innovation and value for personalized medicine.” Ms. Olson was recognized as one of the 10 Best Women Leaders of 2020 by Industry Era. In 2013, she received the “Woman of Wellness Award” for her extraordinary contributions through her volunteer work in oncology. She currently serves as an ambassador with the American Cancer Society through the ResearcHERS: Women Fighting Cancer campaign, which helps fund women-led cancer research. She has written several articles on personalized medicine, molecular diagnostics and business strategy. Ms. Olson has a bachelor’s degree in business from the University of Minnesota and a master’s degree from St. Thomas University in Minnesota. She has held several board positions, and currently serves as a board member of the Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR).
For More Information on
Castle GEP Tests